CA2689581A1 - Composes de cyclobutenedione substitues anti-inflammatoires - Google Patents

Composes de cyclobutenedione substitues anti-inflammatoires Download PDF

Info

Publication number
CA2689581A1
CA2689581A1 CA002689581A CA2689581A CA2689581A1 CA 2689581 A1 CA2689581 A1 CA 2689581A1 CA 002689581 A CA002689581 A CA 002689581A CA 2689581 A CA2689581 A CA 2689581A CA 2689581 A1 CA2689581 A1 CA 2689581A1
Authority
CA
Canada
Prior art keywords
hydroxy
cyclobut
methyl
chloro
tetrahydrofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002689581A
Other languages
English (en)
Inventor
Neil John Press
Simon James Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2689581A1 publication Critical patent/CA2689581A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002689581A 2007-06-06 2008-06-04 Composes de cyclobutenedione substitues anti-inflammatoires Abandoned CA2689581A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07109704 2007-06-06
EP07109704.2 2007-06-06
PCT/EP2008/056902 WO2008148790A1 (fr) 2007-06-06 2008-06-04 Composés de cyclobutènedione substitués anti-inflammatoires

Publications (1)

Publication Number Publication Date
CA2689581A1 true CA2689581A1 (fr) 2008-12-11

Family

ID=38626949

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002689581A Abandoned CA2689581A1 (fr) 2007-06-06 2008-06-04 Composes de cyclobutenedione substitues anti-inflammatoires

Country Status (13)

Country Link
US (1) US8183281B2 (fr)
EP (1) EP2155670B1 (fr)
JP (1) JP2010529079A (fr)
KR (1) KR20100031718A (fr)
CN (1) CN101772485A (fr)
AT (1) ATE554066T1 (fr)
AU (1) AU2008258588B2 (fr)
BR (1) BRPI0812222A2 (fr)
CA (1) CA2689581A1 (fr)
EA (1) EA200901612A1 (fr)
ES (1) ES2386489T3 (fr)
MX (1) MX2009013276A (fr)
WO (1) WO2008148790A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103198C2 (en) * 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
US8648070B2 (en) * 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
WO2013030803A1 (fr) 2011-09-02 2013-03-07 Novartis Ag Sel de choline d'un composé anti-inflammatoire à base de cyclobutènedione substitué
FR2981935B1 (fr) * 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
CZ2014321A3 (cs) * 2014-05-09 2016-01-13 Vysoká škola chemicko- technologická v Praze Dioxocyklobutenylhydrazony a jejich protirakovinné účinky
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
JP2020530848A (ja) * 2017-08-14 2020-10-29 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ３，４−二置換３−シクロブテン−１，２−ジオンおよびその使用
CN111867579B (zh) 2018-01-08 2023-11-24 凯莫森特里克斯股份有限公司 Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法
CN112672791B (zh) 2018-09-21 2023-10-03 辉瑞公司 用作ccr6抑制剂的n-取代二氧代环丁烯基氨基-3-羟基-吡啶甲酰胺
CN109824629B (zh) * 2019-02-27 2022-12-09 南京工业大学 一种利用N-乙酰氨基葡萄糖制备3-氨基-5-(α-氨基乙基)四氢呋喃的方法
EP4021572A1 (fr) 2019-08-28 2022-07-06 Novartis AG Dérivés de 1,3-phényl hétéroaryle substitués et leur utilisation dans le traitement d'une maladie
CN112759549B (zh) * 2019-11-05 2023-07-28 中国医学科学院药物研究所 3-取代氨基-4-((取代吡啶基)氨基)环丁-3-烯-1,2-二酮类化合物
CN112851635B (zh) * 2019-11-28 2022-09-16 中国医学科学院药物研究所 环状砜类化合物及其制备方法、用途和药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166050A (en) * 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
WO2002057230A1 (fr) 2001-01-16 2002-07-25 Smithkline Beecham Corporation Antagonistes des recepteurs de l'il-8
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
MY149050A (en) * 2001-04-16 2013-07-15 Merck Sharp & Dohme 3,4 di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
US7132445B2 (en) * 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2003080053A1 (fr) 2002-03-18 2003-10-02 Schering Corporation Traitements combines pour maladies induites par la chimiokine

Also Published As

Publication number Publication date
US20100125071A1 (en) 2010-05-20
CN101772485A (zh) 2010-07-07
ES2386489T3 (es) 2012-08-21
KR20100031718A (ko) 2010-03-24
JP2010529079A (ja) 2010-08-26
EP2155670A1 (fr) 2010-02-24
AU2008258588A1 (en) 2008-12-11
BRPI0812222A2 (pt) 2014-12-16
US8183281B2 (en) 2012-05-22
MX2009013276A (es) 2010-01-25
AU2008258588A8 (en) 2010-05-13
WO2008148790A8 (fr) 2010-01-07
EP2155670B1 (fr) 2012-04-18
AU2008258588B2 (en) 2011-11-10
WO2008148790A1 (fr) 2008-12-11
EA200901612A1 (ru) 2010-06-30
ATE554066T1 (de) 2012-05-15

Similar Documents

Publication Publication Date Title
AU2008258588B2 (en) Anti -inflammatory substituted cyclobutenedione compounds
US9115087B2 (en) Squaramide derivatives as CXCR2 antagonist
EP2094696B1 (fr) Dérivés de 5-sulfanylméthyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol utilisés comme antagonistes de cxcr2
US20110009429A1 (en) Heterocyclic compounds as inhibitors of cxcr2
EP2086947A1 (fr) Pyrimidines et leur utilisation comme antagonistes du récepteur cxcr2
US20080306064A1 (en) Benzimidazole Derivatives

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130604